Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 10, 2022 16:05 ET
|
Rain Therapeutics Inc
– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data...
Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
November 04, 2022 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the...
Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
November 04, 2022 07:55 ET
|
Rain Therapeutics Inc
- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating...
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
October 27, 2022 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium
October 26, 2022 14:04 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate,...
Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
August 31, 2022 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate,...
Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 04, 2022 16:05 ET
|
Rain Therapeutics Inc
– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 – – Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance; topline data anticipated...
UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
August 04, 2022 10:47 ET
|
Rain Therapeutics Inc
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM...
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
August 04, 2022 08:00 ET
|
Rain Therapeutics Inc
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM...
Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress
May 04, 2022 16:01 ET
|
Rain Therapeutics Inc
– Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than previously guided, now in first half of 2023,...